Abstract
Thymic malignancies are rare tumors where lack of preclinical models adversely affect development of new therapies. Galectin-1 is an important protein in cancer involved in maintaining an immunosuppressive environment. This study examined galectin-1 expression in a large thymic epithelial tumor issue microarray and found elevated expression compared to benign thymus controls. Galectin-1 is a potential therapeutic target in thymic malignancies.
Original language | English (US) |
---|---|
Journal | Clinical Lung Cancer |
DOIs | |
State | Published - Jan 1 2019 |
Keywords
- Thymic malignancy
- Tumor microenvironment
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research